Trials / Completed
CompletedNCT04639817
Trimethoprim-Sulfamethoxazole vs Levofloxacin as Targeted Therapy for Stenotrophomonas Maltophilia Infections: a Retrospective Cohort Study
Trimethoprim-Sulfamethoxazole or Levofloxacin? A Retrospective Cohort Study of Targeted Therapy for Stenotrophomonas Maltophilia Blood Stream and Lower Respiratory Tract Infections
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,621 (actual)
- Sponsor
- National Institutes of Health Clinical Center (CC) · NIH
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study seeks to compare mortality outcomes of levofloxacin and trimethoprim-sulfamethoxazole treated patients who have Stenotrophomonas maltophilia blood stream or lower respiratory tract infections by retrospectively analyzing a propensity-matched cohort from a large dataset of electronic health record data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levofloxacin | Levofloxacin administration |
| DRUG | trimethoprim-sulfamethoxazole | Trimethoprim-sulfamethoxazole administration |
Timeline
- Start date
- 2020-08-14
- Primary completion
- 2021-01-31
- Completion
- 2021-04-27
- First posted
- 2020-11-23
- Last updated
- 2021-04-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04639817. Inclusion in this directory is not an endorsement.